Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51622 | 0.83 | ALDH1A1 (0.52) | MAPTADRA2ALMNAADRA2BADRA2C | |
| SCHEMBL455156 | 0.81 | HCAR3 (0.55) | MAPTADRA2ALMNAADRA2BADRA2C | |
| SCHEMBL4579781 | 0.81 | MAPT (0.51) | MAPTADRA2ALMNAADRA2BADRA2C | |
| SCHEMBL4080966 | 0.80 | LMNA (0.50) | LMNAADRA2BHCAR3KDM4ERAB9A | |
| SCHEMBL10084799 | 0.79 | MAPT (0.52) | MAPTADRA2ALMNAADRA2BADRA2C | |
| SCHEMBL1803092 | 0.79 | ADRA2A (0.53) | MAPTADRA2ALMNAADRA2BADRA2C | |
| SCHEMBL24865263 | 0.78 | ALDH1A1 (0.38) | MAPTLMNAALDH1A1GAAPOLB | |
| SCHEMBL11067507 | 0.78 | PLK1 (0.51) | LMNAADRA2BHCAR3KDM4ERAB9A | |
| SCHEMBL38655892 | 0.78 | PLK1 (0.51) | LMNAADRA2BHCAR3KDM4ERAB9A | |
| Oxalic Acid SCHEMBL9716123 | 0.78 | LMNA (0.55) | MAPTADRA2ALMNAADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431397-B | Benzotriazine free radical compound, preparation method thereof and application thereof in organic memristors and artificial synapses | ZHENGZHOU UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| CN-118929876-B | Flocculant for domestic sewage and preparation method thereof | 辽宁辽河金宇能源集团有限公司科研分公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119431397-A | Benzotriazine free radical compound, preparation method thereof and application thereof in organic memristors and artificial synapses | 郑州大学 | 2025-02-14 | — | — | CN | disclosed |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118929876-A | Flocculant for domestic sewage and preparation method thereof | 辽宁辽河金宇能源集团有限公司科研分公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-08-22 | — | — | US | disclosed |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4037685-B9 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-01-18 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4037685-B1 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2023-09-14 | — | — | US | disclosed |
| CN-116744928-A | Quinolines modulating SERCA and their use for treating diseases | 神经元公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2022020261-A9 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4037685-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | Neurodon Corporation (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-1722863-B1 | MICROCAPSULES WITH UV FILTER ACTIVITY AND PROCESS FOR PRODUCING THEM | DSM IP ASSETS BV (NL) | 2012-02-08 | — | — | EP | disclosed |
| US-6716856-B1 | CELL PROLIFERATIVE DISORDERS OR ALZHEIMER'S DISEASE; REDUCED TOXICITY; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA & TUBJOHN SPA (IT) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885ADRA2A 194/4885LMNA 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.